Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OV101

Small molecule · developed by H. Lundbeck

Phase 3 Most advanced trial (none active)
3 Registered trials

What is OV101?

OV101 (gaboxadol) is a drug studied in Angelman syndrome and Fragile X syndrome, given once daily at bedtime.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Gaboxadol
Drug type
Small molecule
Therapy area
Neurology
Developer
H. Lundbeck A/S
In trials of
OVID
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04106557 Phase 3 Primary Disease or Condition Being Studied: Angelman Syndrome (AS) Completed OVID
NCT03697161 Phase 2 Fragile X Syndrome (FXS) Completed OVID
NCT03109756 Phase 1 Angelman Syndrome Completed OVID

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angelman SyndromeFragile X SyndromeFragile X Syndrome (FXS)

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.